Both ischemic preconditioning and ghrelin administration protect hippocampus from ischemia/reperfusion and upregulate uncoupling protein-2 by Liu, Yajun et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Physiology
Open Access Research article
Both ischemic preconditioning and ghrelin administration protect 
hippocampus from ischemia/reperfusion and upregulate uncoupling 
protein-2
Yajun Liu1,2,4, Lianbi Chen1, Xiaoqun Xu3, Eric Vicaut2 and 
Richard Sercombe*2
Address: 1Institute of Physiology, School of Medicine, Shandong University, Jinan 250012, Shandong, PR China, 2Laboratory of Microcirculation 
Research (EA 3509), University Paris 7, France, 3Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250012, Shandong, PR 
China and 4Medical Pharmacology and Physiology, School of Medicine, University of Missouri, 1 Hospital drive, Columbia, MO 65212, USA
Email: Yajun Liu - liuducky@hotmail.com ; Lianbi Chen - clb@sdu.edu.cn; Xiaoqun Xu - liuducky@hotmail.com; 
Eric Vicaut - eric.vicaut@lrb.aphp.fr; Richard Sercombe* - r.sercombe@orange.fr
* Corresponding author    
Abstract
Background: A major endogenous protective mechanism in many organs against ischemia/reperfusion (I/R)
injury is ischemic preconditioning (IPC). By moderately uncoupling the mitochondrial respiratory chain and
decreasing production of reactive oxygen species (ROS), IPC reduces apoptosis induced by I/R by reducing
cytochrome c release from the mitochondria. One element believed to contribute to reduce ROS production is
the uncoupling protein UCP2 (and UCP3 in the heart). Although its implication in IPC in the brain has been shown
in vitro, no in vivo study of protein has shown its upregulation. Our first goal was to determine in rat hippocampus
whether UCP2 protein upregulation was associated with IPC-induced protection and increased ROS production.
The second goal was to determine whether the peptide ghrelin, which possesses anti-oxidant and protective
properties, alters UCP2 mRNA levels in the same way as IPC during protection.
Results: After global forebrain ischemia (15 min) with 72 h reperfusion (I/R group), we found important neuronal
lesion in the rat hippocampal CA1 region, which was reduced by a preceding 3-min preconditioning ischemia
(IPC+I/R group), whereas the preconditioning stimulus alone (IPC group) had no effect. Compared to control,
UCP2 protein labelling increased moderately in the I/R (+39%, NS) and IPC+I/R (+28%, NS) groups, and
substantially in the IPC group (+339%, P < 0.05). Treatment with superoxide dismutase (10000 U/kg ip) at the
time of a preconditioning ischemia greatly attenuated (-73%, P < 0.001) the increase in UCP2 staining at 72 h,
implying a role of oxygen radicals in UCP2 induction.
Hippocampal UCP2 mRNA showed a moderate increase in I/R (+33%, P < 0.05) and IPC+I/R (+40%, P < 0.05)
groups versus control, and a large increase in the IPC group (+333%, P < 0.001). In ghrelin experiments, the I/
R+ghrelin group (3 daily administrations) showed considerable protection of CA1 neurons versus I/R animals, and
increased hippocampal UCP2 mRNA (+151%, P < 0.001).
Conclusion:  We confirm that IPC causes increased expression of UCP2 protein in vivo, at a moment
appropriate for protection against I/R in the hippocampus. The two dissimilar protective strategies, IPC and
ghrelin administration, were both associated with upregulated UCP2, suggesting that UCP2 may often represent
a final common pathway in protection from I/R.
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Background
Protection against ischemic lesion has been very exten-
sively studied in the heart and brain. One powerful
endogenous mechanism of protection present in these
and other organs is ischemic preconditioning. This con-
sists of a single or a series of brief, non-lethal ischemic
periods which condition the tissue to resist against signif-
icant cell death when subsequently challenged by a nor-
mally lethal ischemia. Delayed protection, which is the
subject of the present study, takes place from 12 h to 7
days after the preconditioning ischemia [1-5], and must
involve transcriptional regulation.
Ischemia of cardiac cells or neurons leads to apoptosis
which occurs via release of cytochrome c from mitochon-
dria [6-10]. This activates the caspase cascade. These
events are triggered in large part by excess mitochondrial
reactive oxygen species (ROS) [7,11-13].
In the heart, as in the brain, ischemic tolerance induced by
preconditioning is associated with modest uncoupling of
the mitochondrial respiratory chain [2,3], which reduces
the production of ROS by respiration. A variety of signal-
ling pathways seems to be involved. One of the mitochon-
drial elements believed to play a role in such
preconditioning are the uncoupling proteins UCP2 and
UCP3. There is clear evidence of increased expression of
UCP2/3 in the heart in this situation [2,14], and more
limited evidence in the brain for UCP2 [15,16] (only
UCP2 is clearly expressed in the brain). In the brain, it has
been shown that new protein expression can be triggered
by large-scale mitochondrial ROS production occurring at
reperfusion [17,18].
With respect to the brain, the uncoupling protein, UCP-2,
has been recently noted to possess a certain neuroprotec-
tive activity [15,16,19,20]. Situated in the inner mito-
chondrial membrane, it is distributed in several brain
regions [19,21]. Its role appears to be to dissipate the pro-
ton electrochemical gradient through the mitochondrial
inner membrane [22,23]. By this means, it mildly uncou-
ples oxidative phosphorylation from respiration,
decreases the inner membrane potential, and reduces ROS
production, especially superoxide, by the respiratory com-
plexes [24,25]. Thus, increased expression of this protein
coincident with ischemia should reduce the production of
ROS in mitochondria and confer protection on cells sub-
ject to I/R. Compatible effects of UCP2 have indeed been
demonstrated in in vitro preparations [15,16], but only
the study by Mattiasson et al [15] has so far provided in
vivo data, in the form of measures of UCP2 mRNA, com-
patible with this possibility in ischemic preconditioning.
Increased protein expression has not yet been demon-
strated.
The peptide ghrelin is an endogenous ligand for the
growth hormone secretagogue (GHS) receptor (GHS-R)
[26]. Although its role in the control of feeding and energy
metabolism is well known, it also exerts protective effects
against I/R injury in the cardiovascular system [27-29] and
the gastro-intestinal system [30-32]. An inhibitory influ-
ence on apoptosis has been reported [28,33].
We recently reported for the first time that post-ischemic
ghrelin administration was protective and anti-apoptotic
in the brain, in rat hippocampus, after global forebrain I/
R [34]. Subsequently, it has been shown that ghrelin-
induced neuroprotection in vitro (glucose-deprivation
lesion) was associated with inhibition of the mitochon-
drial apoptosis pathway (cytochrome c release and cas-
pase-3 activation), and increased Bcl2/Bax ratio [35].
These phenomena are associated with reduced I/R injury
to the hippocampal CA1 neurons after IPC [6,8,36].
Another recent study has confirmed that redox injury and
apoptotic mechanisms could be inhibited by ghrelin in
cortical neurons subject to I/R [37].
Thus, although apparently different in their modes of trig-
gering protection, IPC and ghrelin exert similar strong
protection in the brain, including the hippocampus. Both
are also capable of protecting other organs such as heart
and intestine.
Concerning ghrelin, Chung et al [35] also showed that
this protection was associated with mitochondrial mem-
brane potential stabilization and decreased ROS forma-
tion, compatible with increased activity of UCP2. This
suggests, therefore, that neuroprotection by either ghrelin
or IPC could involve inhibition of the mitochondrial
apoptosis pathway through increased expression of
UCP2. Indeed, it has been shown in different tissues that
ghrelin can induce upregulation of UCP2 and sometimes
UCP3 [38,39]. Furthermore, a recent study in the heart
showed that although IPC can involve different signalling
pathways, these converge finally at the mitochondrial res-
piratory pathway [13].
The experiments undertaken in this study sought to con-
firm that UCP2 protein was effectively over-expressed in
vivo in ischemically preconditioned hippocampus, and to
determine if the production of ROS could be responsible
for this increased expression. Second, by similar measure-
ments of UCP2 mRNA, we determined whether IPC and
ghrelin administration involved similar changes in UCP2
protein transcription when used to attenuate hippocam-
pal ischemic lesion. Our results confirm the increased
UCP2 expression and reveal a striking resemblance in the
final action of ghrelin and IPC.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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Results
UCP2 protein expression in hippocampal neurons after 
IPC
1. Ischemic preconditioning protects CA1 neurons. The
protection afforded by IPC to the CA1 area of the hippoc-
ampus was assessed with anti-NeuN staining. NeuN is a
specific, neuronal protein. Typical images from brains of
the four groups are shown in Fig 1. The I/R group (Fig 1B)
showed a majority of neurons with much reduced, irregu-
lar staining, compared to the three other groups, which
appeared very similar. Thus, the preconditioning stimulus
did not itself cause a significant reduction in normal neu-
rons. Blinded counting of intact neurons gave the result
shown in Fig 1E, indicating a high degree of neuronal pro-
tection in the IPC+I/R group.
2. UCP2 protein immunoreactivity is increased in CA1
neurons after ischemic preconditioning. The variation of
UCP2 protein expression in CA1 pyramidal neurons was
examined by IHC. Two anti-UCP2 antibodies were tested
in the hippocampi of the four groups. Typical results are
shown in Fig 2, obtained with a C-terminal antibody
Ischemic preconditioning reduces the neuronal damage of the hippocampal CA1 region in rats (confocal microscope images of  anti-NeuN staining by indirect immunohistochemistry) Figure 1
Ischemic preconditioning reduces the neuronal damage of the hippocampal CA1 region in rats (confocal 
microscope images of anti-NeuN staining by indirect immunohistochemistry). A: control group; B: I/R group; C: 
IPC+ I/R group; D: IPC group. Scale bar = 30 μm; E: bar graph of results of neuronal counting (performed blinded) expressed 
as number of intact neurons/mm CA1 pyramidal layer (mean ± S.E.M, n = 4 animals). Significant differences were determined 
by repeated measures ANOVA plus Tukey's test. *** P < 0.001 compared to I/R group.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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Expression of UCP-2 in CA1 area of hippocampus (confocal microscope images of UCP2 staining by indirect immunohisto- chemistry) as observed with sc6525 (A, B, C, D) anti-UCP2 (C-terminal antibody) Figure 2
Expression of UCP-2 in CA1 area of hippocampus (confocal microscope images of UCP2 staining by indirect 
immunohistochemistry) as observed with sc6525 (A, B, C, D) anti-UCP2 (C-terminal antibody). A, control; B, I/
R; C, IPC+I/R; D, IPC. NC, negative control obtained in the absence of the anti-UCP2. Scale bar = 30 μm. E: Bar graph of 
results of UCP-2 immunofluorescence (sc6525 images) in the CA1 pyramidal layer, expressed as average intensity after sub-
traction of background fluorescence (mean ± S.E.M, n = 4 animals). Significant differences were determined by repeated meas-
ures ANOVA plus Tukey's test. * P < 0.05 compared to all other groups.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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(sc6525). The general pattern of results found in each
series was very similar, showing very weak staining in the
controls (A), slightly brighter staining in the I/R (B) and I/
R+IPC (C) groups, and much stronger staining in the IPC
group (D). Since the sc6525 antibody gave stronger stain-
ing, we used it for the statistical comparison of the fluores-
cence intensity in the four groups. Absence of staining was
found when this antibody was omitted (Fig 2NC). The
graph (Fig 2E) shows that the intensity in the IPC group
considerably exceeded that of the other three groups. The
fluorescence intensities of the I/R and IPC+I/R groups
were numerically higher than, but not significantly differ-
ent from, those from control. This evaluation comprised a
correction for the differences in background fluorescence
(see methods).
3. Further control experiments. Since doubts about the
specificity and sensitivity of certain anti-UCP2 antibodies
have been expressed [40,41], we performed other control
experiments and examined the staining in detail. The N-
terminal antibody sc 6526 was tested under identical con-
ditions to sc6525 and found to stain the four types of hip-
pocampal sections with an exactly similar pattern (Fig 3a,
b, c, d). In stomach tissue from two control rats and three
rats which fasted for 24 h, we found UCP2 immunoreac-
tivity in 5-6 times more cells in the fasting animals (Fig
3B) than in controls (Fig 3A). Fasting has previously been
Control experiments Figure 3
Control experiments. a, b, c, d, expression of UCP-2 in CA1 area of hippocampus (confocal microscope images of UCP2 
staining by indirect immunohistochemistry) in examples of the 4 groups indicated, as observed with sc6526 (N-terminal anti-
body). A, B, C, indirect immunohistochemical labeling of UCP2 (red) in stomach (A, B, C). The DNA is stained blue with DAPI. 
White arrows in A and B indicate some of the UCP2-positive cells of the mucosal layer. Typically, there are more in the stom-
ach from a fasted animal (B) than from that of a control animal (A). C shows detail of one cell, with an overlapping zone (pink) 
of UCP2 immunoreactivity and DAPI. D1, D2, CA1 neurons of the hippocampus showing pyramidal cells from a control animal 
and an IPC animal respectively. Notice the proximal dendritic staining of UCP2 in the highly stained IPC animal (arrows in D2). 
E, F, high power fields of pyramidal cells in an IPC animal, E with UCP2 staining and F without UCP2 staining. Notice the differ-
ence in the apparent shape and size of pyramidal cell nuclei between control (D1, round unstained nuclei) and IPC animals (F, 
polygonal DAPI-stained nuclei, red arrows). Widespread homogeneous UCP2 immunoreactivity was present in the pyramidal 
cell cytoplasm in the IPC group (E, star); it also appeared interspersed, non-homogeneously, with the DAPI staining. UCP2 
staining with sc6525 except in D (sc6526).BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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shown to increase the UCP2 protein detected by western
blot in the stomach of mice [40]. Fig 3C is an enlargement
of one cell positive for UCP2 immunoreactivity. It reveals
a close relation of UCP2 immunoreactivity and DAPI
staining (pink zone).
Whereas UCP2 staining in the control situation was weak
and limited to a perinuclear halo (Fig 3D1), in some cases
in the IPC group it was observed to invade the proximal
part of the pyramidal cell dendrites (Fig 3D2), as previ-
ously noted [16]. In the IPC-treated brains, in which the
the UCP2 immunoreactivity was always far denser, the
staining pervaded a large part of the cytoplasm and often
appeared intimately related to the DAPI staining of DNA
in the nucleus (Fig 3E, F), the shape of which became less
regular (cf panel D1). Outside the pyramidal cell layer,
small DAPI-stained nuclei of presumed glial cells were not
associated with UCP2 staining (not shown). In the cyto-
plasm of pyramidal neurons, a modest degree of overlap
with NeuN immunoreactivity was noted (not shown).
4. Increase in UCP2 immunoreactivity in IPC brains is
blocked by ROS scavenging. In three groups of rats under-
going IPC treatment, one group received no treatment,
one received intraperitoneal SOD and one received only
vehicle. As shown in Fig 4A, B, C, D, the brains from the
SOD-treated rats showed a dramatic reduction in the
UCP2 immunoreactivity detected at day 3. Indeed, even
the morphological aspect of the remaining UCP2 immu-
noreactivity (Fig 4B) resembled that seen in the non-
ischemic animals (Fig 2A or 3a).
5. The level of UCP2 immunoreactivity fades considerably
between 3 and 6 days after IPC. When groups of rats sub-
jected to IPC were sacrificed at day 6, the UCP2 immuno-
reactivity had decreased significantly to a low level
compared to the high level observed at day 3 (Fig 5B, C).
Thus, a high level of expression of UCP2 was seen at day
3, whereas, although numerically higher, the fluorescence
intensity at day 6 was not significantly different from the
control (Fig 5D).
Comparison of UCP2 mRNA in IPC- and ghrelin-treated 
hippocampi
1. Ischemic preconditioning increases the amount of hip-
pocampal UCP2 mRNA. In a set of parallel experiments,
Effects of SOD treatment on UCP2 immunoreactivity (indirect method) in the hippocampal CA1 area Figure 4
Effects of SOD treatment on UCP2 immunoreactivity (indirect method) in the hippocampal CA1 area. Confo-
cal microscope images of UCP2 immunoreactivity of A: IPC group; B: IPC + SOD group; C: IPC +vehicle group. Notice the 
similarity in the appearance of SOD-treated neurons in B with that of control neurons in Fig 2A. D: Bar graph of fluorescence 
intensities of UCP-2 staining (mean ± S.E.M, n = 4 animals). Scale bar A, B, C = 15 μm. Significant differences were determined 
by repeated measures ANOVA plus Tukey's test. *** P < 0.001 compared to IPC group; ## P < 0.01 compared to IPC + SOD 
group.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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hippocampi from the same four groups as in the IHC
experiments were compared by RT-PCR to compare the
amounts of UCP2 mRNA present (Fig 6). Fig 6A illustrates
a typical gel, the overall results being shown in Fig 6B.
mRNA was increased considerably in the IPC group, but
only moderately (though significantly) in the I/R and
IPC+I/R groups, compared to control. The two intermedi-
ate groups were also significantly different from the IPC
group. This result suggests that a high level of transcrip-
tion of mRNA was induced in the hippocampus by the
IPC treatment. However, in the IPC+I/R group, at the time
of the sacrifice 6 days after IPC, the level had fallen back
to the level of the I/R group.
2. Ghrelin treatment is accompanied by increased
amounts of hippocampal UCP2 mRNA. Fig 7 shows that
the I/R group treated with ghrelin on days 0, 1, and 2 con-
tained significantly increased amounts of UCP2 mRNA in
the hippocampus on day 3, indicating that increased
UCP2 transcription was associated with the protection of
hippocampal neurons. This result is to be set against our
previous results on ghrelin-induced protection: intraperi-
toneal ghrelin on days 0, 1 and 2 afforded a strong protec-
tion of the CA1 neurons against our standard ischemia, as
measured by cell counting in hematoxylin and eosin-
stained sections [34].
Table 1 compares the overall results on CA1 neuroprotec-
tion and hippocampal UCP2 mRNA for IPC and ghrelin
treatment. Both treatments were associated with an aug-
mented level of UCP2 mRNA (columns 3 and 7),
although this was relatively lower in the IPC+I/R group
(column 4), in which the animals were killed on day 6.
Discussion
Only one previous publication has shown evidence of
increased expression of brain UCP2, measured as mRNA
by in situ hybridization, after preconditioning ischemia in
vivo [15]. We have shown in vivo changes in UCP2 mRNA
in parallel with changes in UCP2 protein expression in the
I/R, IPC+I/R and IPC groups compared with control.
Compatible in vitro effects (cell cultures) on UCP2 expres-
sion have been found by Diano et al [16], and Mattiasson
et al [15]. Our results concerning a global forebrain
ischemia model provide more complete in vivo data on
UCP2 protein expression by immunohistochemistry, con-
Effects of post-conditioning ischemia time on UCP2 immunoreactivity in the hippocampal CA1 area Figure 5
Effects of post-conditioning ischemia time on UCP2 immunoreactivity in the hippocampal CA1 area. Confocal 
microscope images of UCP2 immunoreactivity of A: control group; B: D3 group (3 days post-ischemia); C: D6 group (6 days 
post-ischemia). D: Bar graph of fluorescence intensities of UCP2 staining (mean ± SEM, n = 4 animals). Significant differences 
were determined by repeated measures ANOVA plus Tukey's test. ** P < 0.05 compared to Control or D6. Scale bar E, F, G 
= 50 μm.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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firm and extend the mRNA measurements, extend the
data on temporal aspects of UCP2 expression, and dem-
onstrate its dependence on ROS production.
Furthermore, our experiments on mRNA establish for the
first time a similar relationship between two dissimilar
strategies, IPC or ghrelin treatment, which protect against
I/R lesion, and upregulation of a mitochondrial ion trans-
porter protein, UCP2.
IPC-induced neuroprotection and UCP2
Previous studies have clearly shown the neuronal death
induced in the hippocampal CA1 area by global forebrain
ischemia, and the protection afforded by IPC [6,8,42].
Similar findings in the heart concern cardiocytes [2]. We
confirm these results and further show that the precondi-
tioning ischemia does not alone cause significant neuro-
nal damage (Fig 1D, E). In parallel, UCP2 mRNA (Fig 6)
and protein expression (Fig 2) both show strong upregu-
lation of UCP2 after the same preconditioning ischemia
(IPC group versus control). Several points need discus-
sion.
First, one point of the overall paradigm that had to be
optimized by compromise was the question of how long
the reperfusion times should be. Barone et al [1] showed
the preconditioning phenomenon to last 1-7 days and to
require new protein formation before the lethal ischemia.
Puisieux et al [43] confirmed a window of protection of at
least 24-72 h with new protein formation. Schmidt-Kast-
Effects of various treatments on UCP-2 mRNA expression in  IPC experiments Figure 6
Effects of various treatments on UCP-2 mRNA 
expression in IPC experiments. A: RT-PCR of UCP-2 
mRNA in the hippocampal preparations in Control, I/R, 
IPC+I/R and IPC groups. B: Bar graph of mean results (± 
SEM) of RT-PCR determinations of UCP-2 mRNA in hippoc-
ampal preparations, expressed relative to the quantity of β-
actin mRNA (=100%). n = 6 animals. Significant differences 
were determined by repeated measures ANOVA plus 
Tukey's test. *** P < 0.001 compared to all other groups; # P 
< 0.05 compared to CON group.
Effects of various treatments on UCP-2 mRNA expression in  ghrelin experiments Figure 7
Effects of various treatments on UCP-2 mRNA 
expression in ghrelin experiments. RT-PCR of UCP2 
mRNA in the hippocampal preparations in the control group, 
I/R group (vehicle alone), or I/R group treated with ghrelin 
(G). A, B: Typical bands obtained for, respectively, β-actin 
and UCP-2 mRNA. C: Quantitative results expressed with 
respect to β-actin mRNA in each of the three groups. n = 6 
animals. *** significantly different from the control and I/R 
groups, P < 0.001. # significantly different from the control 
group, P < 0.05. ANOVA + Tukey's test.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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ner et al [44] studied the CA1 damage after a single long
ischemia, and determined maximal CA1 damage at 48-72
h. Thus, we chose the delay of 3 days after IPC (until lethal
ischemia or sacrifice) or after lethal ischemia (until sacri-
fice) because (a) it is sufficient to allow important forma-
tion of new protein between the preconditioning and the
lethal ischemia, (b) it is within the range of efficacy of pre-
conditioning, and (c) it is sufficient to allow evaluation of
neuronal lesion after I/R.
Second, because of previous reports on UCP2 antibody
problems (e.g. [40], we compared the antibody used for
relative quantification (C-terminal peptide) with one
raised against an N-terminal peptide (Fig 2 and 3). The
general pattern of expression in the four groups was prac-
tically identical. It is difficult to conceive how two differ-
ent molecules with appropriate peptide sequences (one C-
terminal, one N-terminal) could behave in an apparently
identical manner as observed by the two antibodies. How-
ever, this does not completely exclude the possibility that
the one we used for quantification could bind to addi-
tional proteins. We tested it in the stomach and the clear-
cut labelling of specific mucosal cells was multiplied sev-
eral fold in fasting compared to control animals, exactly
corresponding to the results of the western blot analysis of
Pecqueur et al [40]. This increased expression of UCP2
could be linked to the upregulation of ghrelin in the stom-
ach in fasting animals. We also checked the experiment
with negative controls, i.e. absence of primary antibody
(Fig 2NC). Other workers have considered these two anti-
bodies to be specific to UCP2 [11,15,40,41,45,46], and
Krauss et al [47] showed sc6525 to be unable to stain
UCP2 knock-out mice.
Third, although the two measures of UCP2 upregulation
gave parallel results (compare Figs 2E and 6B), the relative
intergroup differences in values of mRNA/protein expres-
sion seem paradoxical, since the IPC+I/R group values are
only modestly increased. The hypothesis we envisaged is
that UCP2, which is known to reduce mitochondrial ROS
production [23], would protect the neurons from a lethal
ischemia if over-expressed during the appropriate period.
This should be during the lethal ischemia and the subse-
quent reperfusion period. Our evidence is indeed that
UCP2 upregulation was considerable at day 3 after a pre-
conditioning ischemia, at the moment of induction of the
lethal ischemia, as shown by both immunohistochemis-
try of UCP2 protein in the CA1 neurons and RT-PCR of
UCP2 in the hippocampus. In contrast, at day 6 after a
preconditioning ischemia alone (no following lethal
ischemia) (Fig 5D), the UCP2 immunoreactivity had
returned near to baseline. Thus, the time-course of expres-
sion after preconditioning is appropriately high at day 3
to protect the neurons during the phase of high ROS pro-
duction, but at day 6 UCP2 over-expression is probably
much reduced, which is compatible with the known dura-
tion of ischemic preconditioning [1,3]. In the case of pre-
conditioned animals undergoing a second, lethal
ischemia (IPC+I/R group), this lethal (15-min) ischemia
presumably could not induce a large, durable surge of
UCP2 synthesis, probably because the longer duration of
ischemia induces a different pattern of response, which
reduces protein synthesis [48]. Such was the case in the
experiments of Chen et al [11], in which a 10-min lethal
ischemia moderately and increasingly induced UCP2 pro-
tein expression (measured by western blot) from 2 to 18
h, after which it began to decline (24 h). In the experi-
ments of Mattiasson et al [15], a significantly increased
level of UCP2 mRNA was found in vivo at 48 h after a 3-
min ischemia. A more detailed study of the time-course of
ischemia-induced UCP2 upregulation is required to for-
mulate a more precise hypothesis.
Fourth, there is important evidence that excess ROS pro-
duction can induce UCP2 over-expression and activation
[2,14,23,49,50]. Such a large-scale production of ROS
Table 1: Comparison of numbers of surviving CA1 neurons and relative amounts of hippocampal UCP-2 mRNA determined in the 
various groups.
----------IPC experiment ---------- ---Ghrelin experiment---
GROUP 1)CON 2)I/R 3)IPC 4)IPC+I/R 5)CON 6)I/R 7)I/R+G
Number of surviving neurons/mm 
(n = 4/6)
231.6 ± 5.2 41.1a ± 7.7 237.8 ± 12.1 194.1 ± 9.8 251.3 ± 8.7 28.5a ± 7.3 179.5b, c ± 11.5
Relative amount 
(%) of UCP-2 mRNA (n = 6/4)
0.31 ± 0.03 0.44b ± 0.04 1.45a ± 0.02 0.46b ± 0.04 0.32 ± 0.02 0.46b ± 0.03 1.16a ± 0.04
Day of sacrifice D3 D3 D3 D6 D3 D3 D3
mRNA expressed relative to that of β-actin. Day of sacrifice with respect to the first ischemia or sham ischemia (D0). Left 4 columns are set of 
measurements from IPC experiments; right 3 columns are set of measurements from ghrelin experiments. Bold characters: Values taken from Liu 
et al [34]. a: significantly different from all other groups, P < 0.001. b: significantly different from CON, P < 0.05. c: significantly different from I/R, P 
< 0.001. ANOVA + Tukey's test.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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occurs during ischemia, especially at reperfusion. When
Mori et al [51] injected SOD at the time of a precondition-
ing ischemia (focal ischemia model), they observed
strong attenuation of the protection against the subse-
quent lethal ischemia. We thus tested the hypothesis that
UCP2 expression would not be upregulated if ROS were
scavenged at the appropriate time, i.e. beginning at the
time of the preconditioning ischemia. This experiment on
the expression of UCP2 protein in IPC animals treated
with SOD clearly confirmed that most of this increased
expression is abolished. Moreover, this abolition of the
increase in UCP2 immunoreactivity was associated with
the reversion of the immunohistochemical image to the
control pattern (Fig 4A-C), in which UCP2 labelling was
limited to a weak perinuclear halo (Fig 2A).
Although SOD is a large molecule, its passage across the
blood-brain barrier is facilitated by the ischemia itself
which has been shown to alter the permeability of the
microvessels [52]. Furthermore, systemic injection of
SOD was used previously to prevent ROS production fol-
lowing global forebrain ischemia [53], a protocol which
efficiently reduced ischemic damage. Our observations
are strong evidence of the association of UCP2 over-
expression with excess ROS production by the precondi-
tioning ischemia. In contrast, it has been reported that a
preconditioning ischemia does not induce upregulation
of SOD, whether MnSOD or Cu-ZnSOD [44]. Overall, the
present data are extremely coherent with an involvement
of upregulated UCP2 in the IPC-induced protection of the
CA1 area (and probably other hippocampal regions).
Comparison of ghrelin- and IPC-induced effects on UCP2 
mRNA in hippocampus
mRNA coding for receptors to ghrelin (GHS-1a receptors)
have been found in brain, especially the hypothalamus,
the hippocampus, and the anterior pituitary [26]. Both
forms of ghrelin, acylated (octanoyl esterification at the
serine residue 3) and unacylated, are known to cross the
blood-brain barrier [33]. It seems established that only
acylated ghrelin can bind to GHS receptors and release
GH [26], but there may also be a direct, non-growth hor-
mone (GH) releasing type of activity [27,28,33,54], pre-
sumably by another type of receptor. We administered the
acylated form, but it is highly probable that plasmatic
enzymes de-esterify the ser-octanoyl form and vice versa
[55], so that we cannot distinguish which form is active
here.
Neuroprotection by ghrelin was demonstrated by Liu et al
[34] in this 4-vessel occlusion model (see Table 1), and by
Chung et al [35] in a focal ischemia model. Both groups
found inhibition of apoptosis in the hippocampus, and
the latter group reported evidence of inhibition of the
mitochondrial pathway (inhibition of mitochondrial
cytochrome c release and caspase-3 activation, and
increased Bcl2/Bax ratio). Ghrelin has also been shown to
inhibit apoptosis in other models [28,33]. These anti-
apoptosis mechanisms have also been demonstrated in
IPC-induced neuroprotection [6,8,56]. It is probable
therefore that anti-apoptosis mechanisms comprise a sig-
nificant common pathway for neuroprotection by these
two strategies. Furthermore, ghrelin has been shown to
reduce oxidative stress in a rat seizure model [57], to
reduce oxidative stress in the stomach after ischemia and
to inhibit ROS generation in human polymorphonuclear
leukocytes [31], and to inhibit ROS generation in hyperg-
lycemic endothelial cells [58]. In the brain, it has recently
been shown that the action of ghrelin on arcuate nucleus
neurons is driven by a fatty acid oxidation pathway
involving AMPK, CPT1 and free radicals that are scav-
enged by UCP2 [59]. Moreover, in other models, ghrelin
administration has been shown to induce upregulation of
UCP2 and UCP3, in white adipose tissue [38] and liver
[39], and GH increases UCP2 mRNA in adipose tissue and
skeletal muscle [60]. Such considerations led us to deter-
mine whether ghrelin administration and IPC induce sim-
ilar upregulation of UCP2 mRNA in the hippocampus in
a global I/R model.
In the ghrelin experiments, moderate upregulation of hip-
pocampal UCP2 mRNA was seen (Fig 7) in the I/R group,
similar to that found in the I/R group of the IPC series in
Fig 6, and a much larger upregulation in the I/R+ghrelin
group. We followed our previous protocol of 3 post-
ischemic administrations at 24 h intervals which induced
strong neuroprotection [34]. It is likely that this protocol
led to a more persistent upregulation of UCP2 than would
have been induced by a single injection of ghrelin or a sin-
gle preconditioning ischemia.
Table 1 compares the neuroprotective and UCP2-induc-
ing activities of IPC and ghrelin administration. Column
7 indicates that, in a lethal ischemia group, ghrelin
increased both the number of surviving neurons and the
measured amount of UCP2 mRNA. IPC alone (column 3)
increased the measured amount of UCP2 mRNA (without
significant reduction of the number of surviving neurons),
but when it was followed by a lethal ischemia (column 4)
the amount of UCP2 mRNA (on day 6) was reduced,
though still higher than in the control group. This result
parallels the fluorescence intensity of UCP2 immunoreac-
tivity measured at day 6 (Fig 6C), and, as we suggest
above, it can be explained by the fall-off of UCP2 induc-
tion with time. In contrast, this did not occur in the ghre-
lin-treated I/R group, probably because of the threefold
injection of this peptide. The induction of UCP2 expres-
sion by ghrelin may be more rapid than that due to IPC,
perhaps because it is receptor-mediated rather than by the
release of ROS.BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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Conclusion
These coherent data on ghrelin- and IPC-induced protec-
tion afford support for the hypothesis that UCP2 upregu-
lation may often be implicated in different types of
neuroprotection, and perhaps in the protection of other
organs, although the present two strategies of neuropro-
tection clearly have a different time-course of action. The
possible involvement of UCP2 in ghrelin-induced protec-
tion against ischemic lesion has not been previously
explored. Our results add several in vivo lines of evidence
connecting it to IPC protection. Although we did not
establish functional data on UCP2 involvement in protec-
tion, our data encourage further study of the temporal
aspects of its in vivo expression, together with an evalua-
tion of its expression in other models of cerebral ischemia.
Methods
Animal preparation and general protocols
Male Wistar rats weighing 280-330 g were used. All proce-
dures conformed to institutional guidelines for experi-
ments on living animals. Four different types of living
animal preparation were used as follows, based on the
classical 4-vessel global forebrain ischemia model:
1) I/R group: Rats subjected to I/R were prepared by elec-
trocoagulation of the vertebral arteries on day -1, then by
clamping both common carotid arteries for 15 min under
anesthesia on day 0. In each phase they were anesthetized
with pentobarbital (50 mg/kg i.p.). Rectal temperature
was maintained above 37.0°C. The efficiency of the
ischemic manoeuver was appraised by recording the elec-
trocorticogramme (Biopac Student Lab, Biopac Systems,
Inc) and by observing the pupil dilation. The ischemia
was accepted if the EEG became flat (isoelectric signal)
within 1 min, and the pupil dilation attained 100%. Three
days later (day 3), the animal was sacrificed for immuno-
histochemistry (IHC) or RT-PCR (see below).
2) IPC+I/R group: Rats were prepared in the same way for
4-vessel ischemia, but instead of 15 min, the first, precon-
ditioning, ischemia lasted 3 min. On day 3, a second glo-
bal ischemia was induced for 15 min, and three days later
(day 6) the rats were sacrificed under halothane anesthe-
sia.
3) IPC group: Rats were preconditioned only, by inducing,
as described above, an ischemia lasting only 3 min on day
0, then sacrificing them on day 3.
4) Control group (CON): These rats were prepared by per-
forming sham operations for vertebral coagulation and
carotid clamping, then sacrificing them 3 days later.
The immunohistochemical comparison of the above 4
groups comprised experiment A1 (n = 4 animals per
group), and the RT-PCR comparison comprised experi-
ment A2 (n = 6 animals per group).
Experiments on the time-course of UCP2 expression (experiment B)
The results of experiment A led us to a supplementary
experiment, designed to determine how much UCP2
expression persisted at 6 days after the preconditioning
ischemia. Three new groups (n = 4 animals each) were
prepared for comparison, i.e. a control group, an IPC
group constituted as above, and an IPC group killed at day
6.
Experiments on ROS involvement (experiment C)
Since it has been shown that ROS scavenging reduces the
protection induced by IPC [40], we carried out additional
experiments to test the hypothesis that this effect may be
due to the effect of ROS on UCP2 expression. We per-
formed immunohistochemical evaluation of UCP2
expression on animals (n = 4 per group) subjected to pre-
conditioning ischemia (same as 3-day IPC group), to
which we administered superoxide dismutase (SOD,
Sigma, 10000 U/kg i.p.) (SPC group) or vehicle (saline)
(VPC group) 5 min before the brief ischemia. We killed
the rats 3 days later for IHC.
Experiments using ghrelin treatment (experiment D)
In a recent study [34], we evaluated the effects of ghrelin
administration on the number of lesioned pyramidal cells
in the CA1 area from I/R rats in paraformaldehyde-fixed
tissue by hemotoxylin and eosin staining. In the present
work, we made preparations (n = 6 animals per group) for
RT-PCR measurements of the amount of UCP2 mRNA in
the same three groups as previously used, i.e. 1) I/R group,
treated with vehicle; 2) I/R +ghrelin group (I/R+G); 3) con-
trol group treated with vehicle (CON). Ghrelin was
obtained from AnaSpec, Inc. It was dissolved in distilled
water (1 mg/ml) and stored at -20°C until use. For admin-
istration, it was diluted ×10 in 0.9% saline. Treated rats
received 0.4 mg/kg i.p. three times, immediately after the
ischemia, and 24 and 48 h later.
Immunohistochemistry
General tissue treatment
All groups of rats were deeply anesthetized with haloth-
ane and transcardially perfused with heparinized ice-cold
saline followed by 400 ml solution of 4% paraformalde-
hyde in phosphate-buffered saline (PBS), pH 7.4. The
brains were post-fixed overnight in the same fixative, cry-
oprotected in 20% sucrose in PBS for 48 h, then frozen
instantaneously in isopentane at -45°C. Coronal frozen
sections (20 μm thick) cut on a Leica CM3050S cryotome
were collected in PBS, mounted on Superfrost "Plus"
slides (Menzel GmbH & Co KG, Braunschweig), and proc-
essed as follows. After treatment with 5% bovine serum
albumin (BSA) plus 1% triton ×100 in PBS for 30 min, theBMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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sections were incubated for 48 h at 4°C in the primary
antibody diluted in the same BSA/triton ×100 PBS solu-
tion. After several washes, secondary antibody incubation
was performed in the same way for 24 h. In some experi-
ments the sections were incubated with DAPI (10 μg/ml)
for 15 min then rewashed. The sections were coverslipped
using mowiol solution (prepared with N-propyl-gallate,
pH 8). The primary antibodies used were: 1) goat anti-
UCP2 C-terminus (sc-6525), or goat anti-UCP2 N-termi-
nus (sc-6526) both from Santa Cruz Biotechnology,
diluted ×200; 2) mouse anti-NeuN (MAB377, Chemi-
con), diluted ×250. The secondary antibodies were: 1)
rabbit anti-goat Cy3 (C2821, Sigma) or rabbit anti-goat
Alexa 555 (A-21431, Molecular Probes), diluted ×200; 2)
goat anti-mouse Alexa fluor-488 (A-11029, Molecular
Probes) diluted ×100. Negative controls, i.e. omission of
primary antibodies, revealed no staining of either UCP2
or NeuN protein.
Positive controls of UCP2 staining were obtained by
removing stomachs from untreated rats and rats which
had fasted for 24 h. These tissues were fixed by transcar-
dial perfusion of paraformaldehyde as described above,
followed by the same IHC procedures.
Confocal microscopy
In each of the 3 immunohistochemical experiments (A1,
B, C) in which intergroup comparison was intended, 4
runs (n = 4 animals per group) were made, each using one
animal from each group. We thus obtained 4 totally inde-
pendent comparisons. Equivalent sections from each ani-
mal of the different groups were processed under
rigorously identical conditions. Several sets of compari-
sons were made as follows, using either a Bio-Rad MRC
600 (Bio-Rad Microscience, Hertfordshire, UK) with ×25
oil-immersion objective, or a Zeiss LSM 510 META confo-
cal laser microscope (Zeiss, Oberkochen, Germany) with
a Plan Neofluar 40× N.A.1.2 oil-immersion objective or a
Plan Apochromat 63X N.A.1.4 oil-immersion objective
using the LSM510 software v4.0 (Zeiss).
1) For UCP2 staining between the 4 basic groups (control,
I/R, IPC+I/R, IPC), two sections from one animal of each
of the four groups (a total of 8 sections) were used. These
sections were taken at the level 5.7-5.2 mm anterior of the
interaural line. The fluorophore-labelled sections were
examined in a thick central optical plane. This manoeuver
was performed bilaterally in two sites incorporating the
pyramidal layer of each CA1 area (hence 4 sites/section).
The confocal laser-scanning microscope settings used for
quantification were identical for all images of any one
series.
2) Similar procedures were used for the comparison of
IPC groups subject to SOD or vehicle treatment (3
groups), and for the comparison of staining at day 3, day
6 and control. Sections of stomach were similarly com-
pared after identical treatments of the fasted and control
animals.
3) For counting of intact NeuN-stained CA1 neurons, 4
images were acquired from a hippocampal section from
each brain cut at the same level as those used for UCP2
staining measurements.
Measurements of pyramidal cell staining intensity and lesions
After outlining the densely packed pyramidal layer, the
intensity of CA1 UCP2 staining was calculated in arbitrary
units by subtracting the background value (determined
outside the pyramidal layer in the same image) from that
of the defined pyramidal layer. For each of the 4 animals,
the mean value obtained from the 8 images was used in
the statistical comparison between groups. NeuN staining
was used to count in a blinded manner the number of
intact neurons/mm in the CA1 layer.
UCP2 RT-PCR of rat hippocampus
On the appropriate day (see above), the rats were anesthe-
tized with pentobarbital and sacrificed by decapitation.
The brains were quickly removed, and the hippocampi
dissected out, rapidly frozen in liquid nitrogen and stored
at -80°C before use. The specimens were homogenized
and total RNA was isolated using GIT (Guanidine Isothi-
ocyanate) reagent. The first strand cDNA was synthesized
from 1 μg of total RNA using oligo (dT) primer. PCR was
carried out using 5 μl of cDNA template and the specific
sense and antisense primers of β-actin and UCP2. The
primer sequences used were:
β-actin forward, 5'-AAGATCCTGACCGAGCGTGG-3';
β-actin reverse, 5'-CAGCACTGTGTTGGCATAGAGG-3';
UCP2 forward, 5'-CTACAAGACCATTGCACGA-3';
UCP2 reverse 5'-CTCATAGGTGACAAACATTA-3'.
PCR thermal cycling parameters were as follows: 35 cycles
of 94°C for 1 min, 58°C for 1 min, 72°C for 1 min. The
PCR products obtained were loaded on to 2% agarose gels
and evaluated by electrophoresis. The intensities of the
amplified bands were estimated by 1D Image Analysis
Software (Kodak, USA). The levels of UCP2 mRNA expres-
sion was normalised to that of β-actin mRNA.
Statistical methods
The data are expressed as mean ± standard error (S.E.M).
n indicates the number of animals in the groups. Compar-
isons of 3 or 4 groups were made by one-way analysis of
variance (ANOVA) or a repeated measures ANOVA, fol-BMC Physiology 2009, 9:17 http://www.biomedcentral.com/1472-6793/9/17
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lowed by Tukey's test to determine intergroup differences.
Distribution normality was checked. All analyses were
performed using Sigma Stat or Statview software, and dif-
ferences were considered to be statistically significant
when p < 0.05.
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